162 related articles for article (PubMed ID: 34922031)
1. Comparison of New Glucose-Lowering Drugs on the Risk of Pancreatitis in Type 2 Diabetes: A Network Meta-Analysis.
Zhang X; Wang M; Wang X; Zhu Z; Zhang W; Zhou Z; Tang W; Li Q
Endocr Pract; 2022 Mar; 28(3):333-341. PubMed ID: 34922031
[TBL] [Abstract][Full Text] [Related]
2. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Abd El Aziz M; Cahyadi O; Meier JJ; Schmidt WE; Nauck MA
Diabetes Obes Metab; 2020 Apr; 22(4):699-704. PubMed ID: 31750601
[TBL] [Abstract][Full Text] [Related]
3. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
Kramer CK; Ye C; Campbell S; Retnakaran R
JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
[TBL] [Abstract][Full Text] [Related]
4. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.
Yang S; He W; Zhao L; Mi Y
PLoS One; 2022; 17(4):e0267025. PubMed ID: 35421174
[TBL] [Abstract][Full Text] [Related]
5. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.
Zhao M; Sun S; Huang Z; Wang T; Tang H
Clin J Am Soc Nephrol; 2020 Dec; 16(1):70-78. PubMed ID: 33376101
[TBL] [Abstract][Full Text] [Related]
6. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
7. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
[TBL] [Abstract][Full Text] [Related]
8. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
[TBL] [Abstract][Full Text] [Related]
9. Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis.
Li J; Ji C; Zhang W; Lan L; Ge W
J Diabetes Complications; 2023 Jan; 37(1):108362. PubMed ID: 36462459
[TBL] [Abstract][Full Text] [Related]
10. Comparison of New Oral Hypoglycemic Agents on Risk of Urinary Tract and Genital Infections in Type 2 Diabetes: A Network Meta-analysis.
Wang M; Zhang X; Ni T; Wang Y; Wang X; Wu Y; Zhu Z; Li Q
Adv Ther; 2021 Jun; 38(6):2840-2853. PubMed ID: 33999339
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
[TBL] [Abstract][Full Text] [Related]
12. Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials.
Singh AK; Gangopadhyay KK; Singh R
Expert Rev Clin Pharmacol; 2020 Apr; 13(4):461-468. PubMed ID: 32129106
[TBL] [Abstract][Full Text] [Related]
13. Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials.
Wang A; Tang H; Zhang N; Feng X
Diabetes Res Clin Pract; 2022 Jan; 183():109080. PubMed ID: 34626677
[TBL] [Abstract][Full Text] [Related]
14. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
[TBL] [Abstract][Full Text] [Related]
15. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
[TBL] [Abstract][Full Text] [Related]
16. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.
Lando HM; Alattar M; Dua AP
Endocr Pract; 2012; 18(4):472-7. PubMed ID: 22440997
[TBL] [Abstract][Full Text] [Related]
17. The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.
Jin Y; Zhao H; Hou Y; Song G
Acta Diabetol; 2020 Oct; 57(10):1129-1144. PubMed ID: 32300876
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Mannucci E; Monami M
Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
Rehman MB; Tudrej BV; Soustre J; Buisson M; Archambault P; Pouchain D; Vaillant-Roussel H; Gueyffier F; Faillie JL; Perault-Pochat MC; Cornu C; Boussageon R
Diabetes Metab; 2017 Feb; 43(1):48-58. PubMed ID: 27745828
[TBL] [Abstract][Full Text] [Related]
20. Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies.
Tang H; Shao H; Shaaban CE; Yang K; Brown J; Anton S; Wu Y; Bress A; Donahoo WT; DeKosky ST; Bian J; Guo J
J Am Geriatr Soc; 2023 Jul; 71(7):2096-2106. PubMed ID: 36821780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]